Who are PRISTINAMYCIN XRP7263's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Azithropycin according to symptoms, CLDM 1% gel, Linezolid antimicrobial-lock solution, Clarithromycin (ST14), FMS azithromycin tablets, Azithromycin 1gm.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pristinamycin-xrp7263.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

PRISTINAMYCIN XRP7263 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PRISTINAMYCIN XRP7263 (PRISTINAMYCIN XRP7263) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Macrolide antibiotic / Streptogramin. Area: Infectious Disease.

marketed Macrolide antibiotic / Streptogramin Bacterial 50S ribosomal subunit Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

PRISTINAMYCIN XRP7263 (PRISTINAMYCIN XRP7263) — Sanofi. Pristinamycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
PRISTINAMYCIN XRP7263 TARGET	PRISTINAMYCIN XRP7263	Sanofi	marketed	Macrolide antibiotic / Streptogramin	Bacterial 50S ribosomal subunit
Azithropycin according to symptoms	Azithropycin according to symptoms	University Hospital, Montpellier	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit (23S rRNA)
CLDM 1% gel	CLDM 1% gel	GlaxoSmithKline	marketed	Lincosamide antibiotic	Bacterial 50S ribosomal subunit
Linezolid antimicrobial-lock solution	Linezolid antimicrobial-lock solution	Clinica Universidad de Navarra, Universidad de Navarra	marketed	Oxazolidinone antibiotic	Bacterial 50S ribosomal subunit
Clarithromycin (ST14)	Clarithromycin (ST14)	National Taiwan University Hospital	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
FMS azithromycin tablets	FMS azithromycin tablets	University of Taubate	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
Azithromycin 1gm	Azithromycin 1gm	Ain Shams Maternity Hospital	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Macrolide antibiotic / Streptogramin class)

Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PRISTINAMYCIN XRP7263 — Competitive Intelligence Brief. https://druglandscape.com/ci/pristinamycin-xrp7263. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab